CoChat

ONC201 and imipridones: Anti-cancer compounds with clinical efficacy

Open access
Prabhu, Varun Vijay, Morrow, Sara, Rahman Kawakibi, Abed, Zhou, Lanlan, Ralff, Marie, Ray, Jocelyn, Jhaveri, Aakash, Ferrarini, Isacco, Lee, Young, Parker, Cassandra, Zhang, Yiqun, Borsuk, Robyn, Chang, Wen-I, Honeyman, Joshua N., Tavora, Fabio, Carneiro, Benedito, Raufi, Alexander, Huntington, Kelsey, Carlsen, Lindsey, Louie, Anna, Safran, Howard, Seyhan, Attila A., Tarapore, Rohinton S., Schalop, Lee, Stogniew, Martin, Allen, Joshua E., Oster, Wolfgang, El-Deiry, Wafik S. · 2020 · Neoplasia
Cited by 174

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

ONC201 was originally discovered as TNF-Related Apoptosis Inducing Ligand (TRAIL)-inducing compound TIC10. ONC201 appears to act as a selective antagonist of the G protein coupled receptor (GPCR) dopamine receptor D2 (DRD2), and as an allosteric agonist of mitochondrial protease caseinolytic protease P (ClpP). Downstream of target engagement, ONC201 activates the ATF4/CHOP-mediated integrated stress response leading to TRAIL/Death Receptor 5 (DR5) activation, inhibits oxidative phosphorylation via c-myc, and inactivates Akt/ERK signaling in tumor cells. This typically results in DR5/TRAIL-mediated apoptosis of tumor cells; however, DR5/TRAIL-independent apoptosis, cell cycle arrest, or antiproliferative effects also occur. The effects of ONC201 extend beyond bulk tumor cells to include cancer stem cells, cancer associated fibroblasts and immune cells within the tumor microenvironment that can contribute to its efficacy. ONC201 is orally administered, crosses the intact blood brain barrier, and is under evaluation in clinical trials in patients with advanced solid tumors and hematological malignancies. ONC201 has single agent clinical activity in tumor types that are enriched for DRD2 and/or ClpP expression including specific subtypes of high-grade glioma, endometrial cancer, prostate cancer, mantle cell lymphoma, and adrenal tumors. Synergy with radiation, chemotherapy, targeted therapy and immune-checkpoint agents has been identified in preclinical models and is being evaluated in clinical trials. Structure-activity relationships based on the core pharmacophore of ONC201, termed the imipridone scaffold, revealed novel potent compounds that are being developed. Imipridones represent a novel approach to therapeutically target previously undruggable GPCRs, ClpP, and innate immune pathways in oncology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neo.2020.09.005

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Metadata

Authors
Prabhu, V. V., Morrow, S., Rahman Kawakibi, A., Zhou, L., Ralff, M., Ray, J., Jhaveri, A., Ferrarini, I., Lee, Y., Parker, C., Zhang, Y., Borsuk, R., Chang, W.-I., Honeyman, J. N., Tavora, F., Carneiro, B., Raufi, A., Huntington, K., Carlsen, L., Louie, A., Safran, H., Seyhan, A. A., Tarapore, R. S., Schalop, L., Stogniew, M., Allen, J. E., Oster, W., & El-Deiry, W. S.
Venue
Neoplasia
Publisher
Elsevier BV
Published
2020-12
Volume
22
Issue
12
Pages
725-744
ISSN
1476-5586 (ISSN-L)
OpenAlex
W3093671722
Cited by
174
References
9
FWCI
6.09
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.